Cart
sales@molnova.com
LY3405105
CAS No. 2326428-25-3
LY3405105( —— )
Catalog No. M24064 CAS No. 2326428-25-3
1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester is a novel CDK7 inhibitors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 93 | In Stock |
|
| 10MG | 149 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 442 | In Stock |
|
| 100MG | 631 | In Stock |
|
| 200MG | 888 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY3405105
-
NoteResearch use only, not for human use.
-
Brief Description1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester is a novel CDK7 inhibitors.
-
Description1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester is a novel CDK7 inhibitors.
-
In VitroCDK7-IN-4 (compound I) exhibits significant inhibitory activity against NCI-H446, SNU-16, HCC1806, A2780, MCF7, HCT116, and NCI-H460 cells, with IC50 values of 0.01419, 0,02312, 0.02553, 0.02651, 0.03201, 0.04601, and 0.0479, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK7
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2326428-25-3
-
Formula Weight497.64
-
Molecular FormulaC26H39N7O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C(N1CCC(NC2=CC(C)=NC3=C(C(C)C)C=NN23)CC1)OC4CN(C(/C=C/CN(C)C)=O)CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.David Andrew Coates, Carlos montero, bhavin Kumar Rameschandra Patel, et al. Compounds useful for inhibiting cdk7. US 20190144456A1.
molnova catalog
related products
-
THZ2
THZ2, an analogue of THZ1 with improved pharmacokinetic features, is a potent, selective CDK7 inhibitor with IC50 of 13.9 nM, displays a 5-fold improved half-life in vivo compared with THZ1.
-
CDK12-IN-2
CDK12-IN-2 is an effective and selective inhibitor of CDK12 with an IC50 of 52 nM, >100 μM, >10 μM and 16 μM for CDK12, CDK2, CDK7, and CDK9. CDK12-IN-2 can be used in studies about the function of CDK12.
-
JH-VIII-49
JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
